

## Fabian Buller joins as Chief Business Officer in Neurimmune

26 April 2018 | News

Neurimmune develops novel treatments for human diseases with high unmet medical needs



Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, announced that it has appointed Dr. Fabian Buller to the newly created position Chief Business Officer. As an experienced biotech executive, Dr. Buller joins Neurimmune's executive team and brings 8 years of professional experience with biotech and pharma companies.

Prior to joining Neurimmune, Dr. Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. He was instrumental in securing a number of major Biotech-Pharma deals including the sale of Covagen to J&J. Dr. Buller holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.